U.S. patent application number 10/817335 was filed with the patent office on 2004-12-30 for pharmaceutical exipient having improved compressibility.
This patent application is currently assigned to J. Rettenmaier & Soehne GmbH + Co. KG. Invention is credited to Hunter, Edward A., Sherwood, Bob E., Staniforth, John N..
Application Number | 20040265374 10/817335 |
Document ID | / |
Family ID | 27408972 |
Filed Date | 2004-12-30 |
United States Patent
Application |
20040265374 |
Kind Code |
A1 |
Staniforth, John N. ; et
al. |
December 30, 2004 |
Pharmaceutical exipient having improved compressibility
Abstract
A microcrystalline cellulose-based excipient having improved
compressibility, whether utilized in direct compression, dry
granulation or wet granulation formulations, is disclosed. The
excipient is an agglomerate of microcrystalline cellulose particles
and from about 0.1% to about 20% silicon dioxide particles, by
weight of microcrystalline cellulose, wherein the microcrystalline
cellulose and silicon dioxide are in intimate association with each
other. The silicon dioxide utilized in the novel excipient has a
particle size from about 1 nanometer to about 100 microns. Most
preferably, the silicon dioxide is a grade of colloidal silicon
dioxide. An extra low moisture excipient is provided which exhibits
improved compressibility as compared to conventional
microcrystalline cellulose, while providing a moisture content of
of from about 0.5 to 2.5% LOD, preferably between about 0.5 and
about 1.8%, more preferably between 0.8 and 1.5%, and most
preferably between about 0.8 and about 1.2%.
Inventors: |
Staniforth, John N.; (Bath,
GB) ; Sherwood, Bob E.; (Amenia, NY) ; Hunter,
Edward A.; (Cadosia, NY) |
Correspondence
Address: |
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK
NY
10018
US
|
Assignee: |
J. Rettenmaier & Soehne GmbH +
Co. KG
Rosenberg
DE
|
Family ID: |
27408972 |
Appl. No.: |
10/817335 |
Filed: |
April 2, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10817335 |
Apr 2, 2004 |
|
|
|
10266518 |
Oct 8, 2002 |
|
|
|
6746693 |
|
|
|
|
10266518 |
Oct 8, 2002 |
|
|
|
09384130 |
Aug 27, 1999 |
|
|
|
6471994 |
|
|
|
|
09384130 |
Aug 27, 1999 |
|
|
|
08992073 |
Dec 17, 1997 |
|
|
|
6103219 |
|
|
|
|
08992073 |
Dec 17, 1997 |
|
|
|
08724613 |
Sep 30, 1996 |
|
|
|
5725884 |
|
|
|
|
08724613 |
Sep 30, 1996 |
|
|
|
08370576 |
Jan 9, 1995 |
|
|
|
5585115 |
|
|
|
|
Current U.S.
Class: |
424/464 ;
264/109 |
Current CPC
Class: |
A61K 9/2018 20130101;
A61K 9/205 20130101; Y10S 977/906 20130101; A61K 9/2054 20130101;
A61K 9/2013 20130101; A61K 9/2036 20130101; A61K 9/2009
20130101 |
Class at
Publication: |
424/464 ;
264/109 |
International
Class: |
A61K 009/20; A61K
009/14 |
Claims
1. A method for preparing a tablet, comprising the steps of:
forming an aqueous slurry containing a mixture of microcrystalline
cellulose in the form of a wet cake and silicon dioxide having a
particle size from about 1 nm to about 100 .mu.m; drying said
slurry to obtain an excipient comprising a plurality of
agglomerated particles of microcrystalline cellulose in intimate
association with said silicon dioxide, the amount of silicon
dioxide being from about 0.1% to about 20% relative to the amount
of microcrystalline cellulose, by weight; mixing an active
ingredient with said excipient in a ratio from about 1:99 to about
99:1 to obtain a mixture; compressing said mixture into a
tablet.
2. The method of claim 1, wherein said silicon dioxide is colloidal
silicon dioxide, and further comprising wet granulating said
mixture prior to compressing said mixture into said tablet.
3. (canceled)
4. The method of claim 1, wherein said drying is accomplished via
spray drying such that the resultant excipient particles have an
average particle size from about 30 .mu.m to about 250 .mu.m.
5. The method of claim 1, wherein the resultant excipient particles
have a bulk density from about 0.2 g/ml to about 0.6 g/ml.
6. (canceled)
7. The method of claim 2, further comprising adding a further
amount of said excipient to said wet granulated mixture, prior to
compressing said mixture into a tablet.
8. The method of claim 1, wherein said drying further comprises
drying said slurry such that the resultant excipient particles have
a moisture content of from about 0.5 to about 15%.
9. The method of claim 1, wherein said drying further comprises
drying said slurry such that the resultant excipient particles have
a moisture content of from about 0.5 to about 2.5%.
10. The method of claim 1, wherein said drying further comprises
drying said slurry such that the resultant excipient particles have
a moisture content of from about 0.5 to about 1.8%.
11. The method of claim 1, wherein said drying further comprises
drying said slurry such that the resultant excipient particles have
a moisture content of from about 0.8 to about 1.5%.
12. The method of claim 1, wherein said drying further comprises
drying said slurry such that the resultant excipient particles have
a moisture content of from about 0.8 to about 1.2%.
13-38. (canceled)
39. A method for preparing a tablet, comprising the steps of: (a)
forming an aqueous slurry of microcrystalline cellulose in the form
of wet cake; (b) forming an aqueous slurry of silicon dioxide
having a particle size of from about 1 to about 100 .mu.m; (c)
separately introducing said microcrystalline slurry and said
silicon dioxide slurry separately into a drying apparatus for
combination therein, to obtain an excipient comprising a plurality
of agglomerated particles of microcrystalline cellulose in intimate
association with said silicon dioxide, the amount of silicon
dioxide being from about 0.1% to about 20% relative to the amount
of microcrystalline cellulose, by weight; (d) mixing an active
ingredient with said excipient in a ratio of from about 1:99 to
about 99:1 to obtain a mixture; (e) compressing said mixture into a
tablet.
40. The method of claim 39, wherein said silicon dioxide is
colloidal silicon dioxide, and further comprising wet granulating
said mixture prior to compressing said mixture into said
tablet.
41. The method of claim 39, wherein said drying is accomplished via
spray drying such that the resultant excipient particles have an
average particle size from about 10 .mu.m to about 1,000 .mu.m.
42. The method of claim 39, wherein said drying is accomplished via
spray drying such that the resultant excipient particles have an
average particle size from about 30 .mu.m to about 250 .mu.m.
43. The method of claim 39, wherein the resultant excipient
particles have a bulk density from about 0.2 g/ml to about 0.6
g/ml.
44. The method of claim 39, wherein the resultant excipient
particles have a bulk density of from about 0.35 g/ml to about 0.55
g/ml.
45. The method of claim 40, further comprising adding a further
amount of said excipient to said wet granulated mixture, prior to
compressing said mixture into a tablet.
46. The method of claim 39, wherein said drying further comprises
drying such that the resultant excipient particles have a moisture
content of from about 0.5 to about 15%.
47. The method of claim 39, wherein said drying further comprises
drying such that the resultant excipient particles have a moisture
content of from about 0.5 to about 2.5%.
48. The method of claim 39, wherein said drying further comprises
drying such that the resultant excipient particles have a moisture
content of from about 0.5 to about 1.8%.
49. The method of claim 39, wherein said drying further comprises
drying such that the resultant excipient particles have a moisture
content of from about 0.8 to about 1.5%.
50. The method of claim 39, wherein said drying further comprises
drying such that the resultant excipient particles have a moisture
content of from about 0.8 to about 1.2%.
51. The method of claim 1, wherein said drying is accomplished via
spray drying such that the resultant excipient particles have an
average particle size from about 10 .mu.m to about 1,000 .mu.m.
52. The method of claim 51, wherein the resultant excipient
particles have a bulk density of from about 0.35 g/ml to about 0.55
g/ml.
Description
[0001] This is a continuation-in-part of U.S. application Ser. No.
08/992,073 filed Dec. 17, 1997, which is a continuation of U.S.
application Ser. No. 08/724,613 filed Sep. 30, 1996, which is a
divisional of U.S. application Ser. No. 08/370,576, filed Jan. 9,
1995, now U.S. Pat. No. 5,585,115. The entire disclosures of U.S.
application Ser. Nos. 08/992,073, 08/724,613, and 08/370,576 are
hereby incorporated by reference.
BACKGROUND OF THE INVENTION
[0002] The present invention relates to a novel excipient for use
in the manufacture of pharmaceuticals, and in particular, solid
dosage forms such as tablets which include one or more active
ingredients.
[0003] In order to prepare a solid dosage form containing one or
more active ingredients (such as drugs), it is necessary that the
material to be compressed into the dosage form possess certain
physical characteristics which lend themselves to processing in
such a manner. Among other things, the material to be compressed
must be free-flowing, must be lubricated, and, importantly, must
possess sufficient cohesiveness to insure that the solid dosage
form remains intact after compression.
[0004] In the case of tablets; the tablet is formed by pressure
being applied to the material to be tabletted on a tablet press. A
tablet press includes a lower punch which fits into a die from the
bottom and a upper punch having a corresponding shape and dimension
which enters the die cavity from the top after the tabletting
material fills the die cavity. The tablet is formed by pressure
applied on the lower and upper punches. The ability of the material
to flow freely into the die is important in order to insure that
there is a uniform filling of the die and a continuous movement of
the material from the source of the material, e.g. a feeder hopper.
The lubricity of the material is crucial in the preparation of the
solid dosage forms since the compressed material must be readily
ejected from the punch faces.
[0005] Since most drugs have none or only some of these properties,
methods of tablet formulation have been developed in order to
impart these desirable characteristics to the material(s) which is
to be compressed into a solid dosage form. Typically, the material
to be compressed into a solid dosage form includes one or more
excipients which impart the free-flowing, lubrication, and cohesive
properties to the drug(s) which is being formulated into a dosage
form.
[0006] Lubricants are typically added to avoid the material(s)
being tabletted from sticking to the punches. Commonly used
lubricants include magnesium stearate and calcium stearate. Such
lubricants are commonly included in the final tabletted product in
amounts of less than 1% by weight.
[0007] In addition to lubricants, solid dosage forms often contain
diluents. Diluents are frequently added in order to increase the
bulk weight of the material to be tabletted in order to make the
tablet a practical size for compression. This is often necessary
where the dose of the drug is relatively small.
[0008] Another commonly used class of excipients in solid dosage
forms are binders. Binders are agents which impart cohesive
qualities to the powdered material(s). Commonly used binders
include starch, and sugars such as sucrose, glucose, dextrose, and
lactose.
[0009] Disintegrants are often included in order to ensure that the
ultimately prepared compressed solid dosage form has an acceptable
disintegration rate in an environment of use (such as the
gastrointestinal tract). Typical disintegrants include starch
derivatives and salts of carboxymethylcellulose.
[0010] There are three general methods of preparation of the
materials to be included in the solid dosage form prior to
compression: (1) dry granulation; (2) direct compression; and (3)
wet granulation.
[0011] Dry granulation procedures may be utilized where one of the
constituents, either the drug or the diluent, has insufficient
cohesive or flow properties to be tabletted. The method includes
mixing the ingredients, slugging the ingredients, dry screening,
lubricating and finally compressing the ingredients.
[0012] In direct compression, the powdered material(s) to be
included in the solid dosage form is compressed directly without
modifying the physical nature of the material itself.
[0013] The wet granulation procedure includes mixing the powders to
be incorporated into the dosage form in, e.g., a twin shell blender
or double-cone blender and thereafter adding solutions of a binding
agent to the mixed powders to obtain a granulation. Thereafter, the
damp mass is screened, e.g., in a 6- or 8-mesh screen and then
dried, e.g., via tray drying, the use of a fluid-bed dryer,
radio-frequency dryer, microwave, vacuum, or infra-red dryer.
[0014] The use of direct compression is limited to those situations
where the drug or active ingredient has a requisite crystalline
structure and physical characteristics required for formation of a
pharmaceutically acceptable tablet. On the other hand, it is well
known in the art to include one or more excipients which make the
direct compression method applicable to drugs or active ingredients
which do not possess the requisite physical properties. For solid
dosage forms wherein the drug itself is to be administered in a
relatively high dose (e.g., the drug itself comprises a substantial
portion of the total tablet weight), it is necessary that the
drug(s) itself have sufficient physical characteristics (e.g.,
cohesiveness) for the ingredients to be directly compressed.
[0015] Typically, however, excipients are added to the formulation
which impart good flow and compression characteristics to the
material as a whole which is to be compressed. Such properties are
typically imparted to these excipients via a pre-processing step
such as wet granulation, slugging, spray drying, spheronization, or
crystallization. Useful direct compression excipients include
processed forms of cellulose, sugars, and dicalcium phosphate
dihydrate, among others.
[0016] A processed cellulose, microcrystalline cellulose, has been
utilized extensively in the pharmaceutical industry as a direct
compression vehicle for solid dosage forms. Microcrystalline
cellulose is commercially available under the tradename
EMCOCEL.RTM. from Edward Mendell Co., Inc. and as Avicel.RTM. from
FMC Corp. Compared to other directly compressible excipients,
microcrystalline cellulose is generally considered to exhibit
superior compressibility and disintegration properties.
[0017] Another limitation of direct compression as a method of
tablet manufacture is the size of the tablet. If the amount of
active ingredient is high, a pharmaceutical formulator may choose
to wet granulate the active with other excipients to attain an
acceptably sized tablet with the desired compact strength. Usually
the amount of filler/binder or excipients needed in wet granulation
is less than that required for direct compression since the process
of wet granulation contributes to some extent toward the desired
physical properties of a tablet. Thus, despite the advantages of
direct compression (such as reduced processing times and costs),
wet granulation is widely used in the industry in the preparation
of solid dosage forms. Many of those skilled in the art prefer wet
granulation as compared to direct compression because this method
has a greater probability of overcoming any problems associated
with the physical characteristics of the various ingredients in the
formulation, thereby providing a material which has the requisite
flow and cohesive characteristics necessary to obtain an acceptable
solid dosage form.
[0018] The popularity of the wet granulation process as compared to
the direct compression process is based on at least three
advantages. First, wet granulation provides the material to be
compressed with better wetting properties, particularly in the case
of hydrophobic drug substances. The addition of a hydrophilic
excipient makes the surface of a hydrophobic drug more hydrophilic,
easing disintegration and dissolution. Second, the content
uniformity of the solid dosage forms is generally improved. Via the
wet granulation method, all of the granules thereby obtained should
contain approximately the same amount of drug. Thus, segregation of
the different ingredients of the material to be compressed (due to
different physical characteristics such as density) is avoided.
Segregation is a potential problem with the direct compression
method. Finally, the particle size and shape of the particles
comprising the granulate to be compressed are optimized via the wet
granulation process. This is due to the fact that when a dry solid
is wet granulated, the binder "glues" particles together, so that
they agglomerate in the granules which are more or less
spherical.
[0019] Due to the popularity of microcrystalline cellulose,
pharmaceutical formulators have deemed it desirable to include this
excipient in a formulation which is wet granulated prior to
tabletting. Unfortunately, currently-available microcrystalline
cellulose does not hold to the typical principle that the amount of
filler/binder needed in wet granulation is less than that in direct
compression. It is known that the exposure of the microcrystalline
cellulose to moisture in the wet granulation process severely
reduces the compressibility of this excipient. The loss of
compressibility of microcrystalline cellulose is particularly
problematic where the formulation dictates that the final product
will be relatively large in the environment of use. For example, if
a pharmaceutical formulator desires to prepare a solid oral dosage
form of a high dose drug, and the use of the wet granulation
technique is deemed necessary, the loss of compressibility of the
microcrystalline cellulose dictates that a larger amount of this
material may be needed to obtain an acceptably compressed final
product. The additional amount of microcrystalline cellulose needed
adds cost to the preparation, but more importantly adds bulk,
making the product more difficult to swallow.
[0020] The loss of compressibility of microcrystalline cellulose
when exposed to wet granulation has long been considered a problem
in the art for which there has been no satisfactory solution.
[0021] Attempts have been made to provide an excipient having high
compressibility, a small bulk (high apparent density), and good
flowability, while being capable of providing satisfactory
disintegration of the solid dosage form, which is applicable to wet
granulation as well as to dry granulation and direct compression
methods for preparation of solid dosage forms.
[0022] For example, U.S. Pat. No. 4,159,345 (Takeo, et al.)
describes an excipient which consists essentially of a
microcrystalline cellulose having an average degree of
polymerization of 60 to 375 and obtained through acid hydrolysis or
alkaline oxidative degradation of a cellulosic substance selected
from linters, pulps and regenerated fibers. The microcrystalline
cellulose is said to be a white cellulosic powder having an
apparent specific volume of 1.6-3.1 cc/g, a repose angle of
35.degree. to 42.degree., a 200-mesh sieve residue of 2 to 80% by
weight and a tapping apparent specific volume of at least 1.4
cc/g.
[0023] In U.S. Pat. No. 4,744,987 (Mehra, et al.), a particulate
co-processed microcrystalline cellulose and calcium carbonate
composition is described wherein the respective components are
present in a weight ratio of 75:25 to 35:65. The co-processed
composition is said to be prepared by forming a well-dispersed
aqueous slurry of microcrystalline cellulose and calcium carbonate
and then drying the slurry to yield a particulate product. The two
components employed in forming the well-dispersed aqueous slurry
are microcrystalline cellulose and calcium carbonate. The patent
notes that "[t]he microcrystalline cellulose is preferably wet cake
from a conventional microcrystalline cellulose manufacturing
process. The wet cake is material which has not yet been dried,
sometimes termed `never dried` or hydrocellulose, to yield a
conventional microcrystalline cellulose free-flowing powder
product." Alternatively "[t]he microcrystalline cellulose source
may also be conventional product, which has already been dried."
The combination of microcrystalline cellulose and calcium carbonate
is said to provide a lower cost excipient which has tableting
characteristics similar to those of microcrystalline cellulose and
which would satisfy a need for an economical excipient with good
performance that is desired by the vitamin market.
[0024] European Patent Application EP 0609976A1 (assigned to Asahi
Kasei Kabushiki Kaisha) describes an excipient comprising white
powdery microcrystalline cellulose having an average degree of
polymerization of from 100 to 375, preferably from 190 to 210, and
an acetic acid holding capacity of 280% or more, preferably from
290 to 370%. The excipient is said to exhibit high compactability
and a high rate of disintegration and is said to be obtained by
heat-treating an aqueous dispersion of purified cellulose
particles, which has a solids content of 40% or less by weight, at
100.degree. C. or more, followed by drying, or by subjecting an
aqueous dispersion of purified cellulose particles having a solids
content of 23% or less by weight to thin film-forming treatment and
drying the resultant thin film. The excipient is said to possess a
high compressibility, and a good balance of compactability and rate
of disintegration.
[0025] There still remains a need in the industry for a
pharmaceutical excipient which possesses excellent compressibility
whether utilized in a direct compression or wet granulation
procedure.
OBJECTS AND SUMMARY OF THE INVENTION
[0026] It is an object of the present invention to provide an
excipient which is useful in a variety of applications, and which
may be utilized in direct compression or wet granulation
methods.
[0027] It is a further object of the present invention to provide
an excipient useful in direct compression methods which has
improved compressibility relative to microcrystalline
cellulose.
[0028] It is a further object of the present invention to provide
an excipient useful in wet granulation methods which has improved
compressibility relative to microcrystalline cellulose.
[0029] It is a further object of the present invention to provide a
free-flowing excipient which has excellent compressibility
properties when utilized in direct compression or wet granulation
methods, and which furthermore possesses pharmaceutically
acceptable disintegration properties.
[0030] It is a further object of the present invention to provide
an improved microcrystalline cellulose excipient in which the
microcrystalline cellulose has not been chemically altered, and
which has improved compressibility relative to "off-the-shelf"
commercially available microcrystalline cellulose.
[0031] It is a further object of the present invention to provide a
solid dosage form which includes one or more active ingredients and
the improved microcrystalline cellulose excipient of the present
invention.
[0032] It is a further object of the present invention to provide
an oral solid dosage form for one or more drugs which is economical
to manufacture, which maintains its integrity during storage, and
which possesses excellent disintegration and dissolution properties
when exposed, e.g., to gastrointestinal fluid.
[0033] In accordance with the above objects and others which will
be obvious to those skilled in the art, the present invention is
directed to an excipient comprising a particulate agglomerate of
coprocessed microcrystalline cellulose and from about 0.1% to about
20% silicon dioxide, by weight of the microcrystalline cellulose,
the microcrystalline cellulose and silicon dioxide being in
intimate association with each other, and the silicon dioxide
portion of the agglomerate being derived from a silicon dioxide
having a particle size from about 1 nanometer (nm) to about 100
microns (.mu.m), based on average primary particle size.
[0034] In preferred embodiments, the silicon dioxide comprises from
about 0.5% to about 10% of the excipient, and most preferably from
about 1.25% to about 5% by weight relative to the microcrystalline
cellulose.
[0035] In additional preferred embodiments of the invention, the
silicon dioxide has a particle size from about 5 nm to about 40
.mu.m, and most preferably from about 5 nm to about 50 .mu.m.
[0036] In preferred embodiments of the present invention, the
silicon dioxide is further characterized by a surface area from
about 10 m.sup.2/g to about 500 m.sup.2/g, preferably from about 50
M.sup.2/g to about 500 m.sup.2/g, and more preferably from about
175 m.sup.2/g to about 350 m.sup.2/g.
[0037] The present invention is further directed to an aqueous
slurry useful in the preparation of a compressible excipient useful
in dry and wet granulation formulation methods, comprising a
mixture of microcrystalline cellulose in the form of a wet cake
(i.e. hydrocellulose or hydrolyzed cellulose) and from about 0.1%
to about 20% silicon dioxide, by weight relative to the
microcrystalline cellulose, the silicon dioxide having a particle
size from about 1 nm to about 100 .mu.m. The solids content of the
aqueous slurry is from about 0.5% to about 25%, by weight,
preferably from about 15% to about 20% by weight, and most
preferably from about 17% to about 19% by weight.
[0038] The present invention is further directed to a mixture of an
active ingredient(s) and an excipient comprising a particulate
agglomerate of coprocessed microcrystalline cellulose and from
about 0.1% to about 20% silicon dioxide, by weight of the
microcrystalline cellulose, the microcrystalline cellulose and
silicon dioxide being in intimate association with each other, and
the silicon dioxide having a particle size from about 1 nm to about
100 .mu.m. The ratio of active ingredient to excipient is from
about 1:99 to about 99:1, by weight.
[0039] The present invention is further directed to a granulate of
an active ingredient(s) and the novel excipient described herein,
wherein the active ingredient(s) and excipient have been subjected
to a wet granulation procedure.
[0040] The present invention is further directed to a compressed
solid dosage form comprising an active ingredient(s) and the novel
excipient described herein, wherein the active ingredient(s) and
excipient have been directly compressed into the solid dosage form
or have been subjected to a wet granulation procedure and
thereafter compressed into the solid dosage form. The compressed
solid dosage form provides a suitable immediate release dissolution
profile of the active ingredient(s) when exposed to aqueous
solutions during in-vitro dissolution testing, and provides a
release of drug in an environment of use which is considered
bioavailable. In further embodiments of the invention, the
dissolution profile of the solid dosage form is modified to provide
a controlled or sustained release dissolution profile.
[0041] The present invention is further directed to a method of
maintaining and/or enhancing the compressibility of
microcrystalline cellulose. The method includes forming an aqueous
slurry containing a mixture of microcrystalline cellulose in the
form of a wet cake (i.e. hydrocellulose or hydrolyzed cellulose)
and silicon dioxide having a particle size from about 1 nm to about
100 .mu.m, and drying the slurry to obtain microcrystalline
cellulose-based excipient particles in which the silicon dioxide
particles have been integrated with the microcrystalline cellulose
particles. Within this aspect of the invention, the slurry contains
from about 0.5% to about 25% by weight microcrystalline cellulose
in the form of a wet cake, with amounts of from about 15% to about
20% being preferred. Furthermore, the slurry contains from about
0.25% to about 5% by weight silicon dioxide.
[0042] The novel excipient described herein is free-flowing,
possesses excellent disintegration properties, and importantly, in
certain embodiments possesses improved compressibility relative to
normal "off-the-shelf" commercially available microcrystalline
cellulose when directly compressed. The advantages of the novel
excipient described herein are especially realized in
pharmaceutical formulations prepared using wet granulation
techniques. When utilized in wet granulation techniques, the novel
excipient surprisingly provides a compressibility which is
substantially improved in preferred embodiments in comparison to
the compressibility of normal "off-the-shelf" commercially
available microcrystalline cellulose used in wet granulation and is
even comparable to "off-the-shelf" microcrystalline cellulose used
in direct compression techniques. In other embodiments, the novel
excipient surprisingly provides a compressibility which is
substantially superior to the compressibility of normal
"off-the-shelf" commercially available microcrystalline cellulose
used in direct compression techniques.
[0043] In accordance with another embodiment of the present
invention, an extra low moisture excipient is provided which
comprises a particulate agglomerate of coprocessed microcrystalline
cellulose and from about 0.1% to about 20% silicon dioxide, by
weight of the microcrystalline cellulose, the microcrystalline
cellulose and silicon dioxide being in intimate association with
each other, and the silicon dioxide portion of the agglomerate
being derived from a silicon dioxide having a particle size from
about 1 nanometer (nm) to about 100 microns (.mu.m), based on
average primary particle size, the excipient having a moisture
content of from about 0.5 to 2.5 LOD (loss on drying), preferably
between about 0.5 and 1.8 LOD, more preferably between about 0.5
and about 1.5% LOD, and most preferably between about 0.8 and about
1.2% LOD. The excipient in accordance with this embodiment is
particularly suitable for use with moisture sensitive drugs because
of its relatively low moisture content. In fact, the extra low
moisture excipient in accordance with the invention exhibits a
similar compressibility to conventional microcrystalline cellulose
products having moisture content of 5-6% (such as Emcocel.RTM.
90M), and superior compressibility to conventional extra low
moisture microcrystalline cellulose products (such as Emcocel.RTM.
XLM 90) having moisture contents of about 1.2%. Moreover, it is
believed that the extra low moisture excipient in accordance with
the invention, when directly compressed with a moisture sensitive
drug, provides a drug product which is at least as stable as drug
products made with conventional extra low moisture microcrystalline
cellulose, while providing improved compressibility.
[0044] Moisture sensitive drugs which may be used with the extra
low moisture MCC-SiO.sub.2 in accordance with the present invention
include: acetysalicylic acid, aminophylline, ascorbic acid,
atenolol, betahistine mesylate, calcium chloride, captopril,
carbachol, carpronium chloride, cefaclor, cefadroxil, cephrabine,
chlorophyllin sodium-copper salt, choline salicylate, choline
theophyllinate, citicoline, clindamycin HCl, cyanocobalamin,
desipramine HCl, dexamethazone phosphate disodium salt, diclofenac
sodium, dimethylaminoethyl ester dihydrochloride, disopyramide
phosphate, divalproex sodium, ethionamide, fenoprofen calcium,
gemfibrozil, hexamethonium bromide, isosorbide, L-proline
meprobamate, methocarbamol, methyldopa, oxtriphylline,
oxytetracycline HCl, panthenol, piracetam, plant extracts (Querci
Folium extract, Mallot Cortex extract, Equisetum arvense extract,
etc.), procainamide HCl, procainamide hydrochloride, ranitine HCl,
reserpilic acid, rifamprin lincomycin HCl, sodium valproate,
tetracycline HCl, thiamine Hcl, clavlenic acid and salts thereof,
polymixin, herbals, herbal extracts, nutritional products,
nitroglycerin, alkaloid salts, streptomycin, idoxuridine, and
tolazoline hydrochloride.
[0045] The present invention is further directed to a method of
preparing an extra low moisture excipient. The method includes
forming an aqueous slurry containing a mixture of microcrystalline
cellulose in the form of a wet cake (i.e. hydrocellulose or
hydrolyzed cellulose) and silicon dioxide having a particle size
from about 1 nm to about 100 .mu.m, and drying the slurry to obtain
microcrystalline cellulose-based excipient particles which have a
moisture content of from about about 0.5 to 2.5 LOD (loss on
drying), preferably between about 0.5 and 1.8 LOD, more preferably
between about 0.5 and about 1.5% LOD, and most preferably between
about 0.8 and about 1.2% LOD, and in which the silicon dioxide
particles have been integrated with the microcrystalline cellulose
particles. Within this aspect of the invention, the slurry contains
from about 0.5% to about 25% by weight microcrystalline cellulose
in the form of a wet cake, with amounts of from about 15% to about
20% being preferred. Furthermore, the slurry contains from about
0.05% to about 5% by weight silicon dioxide.
[0046] The term "environmental fluid" is meant for purposes of the
invention to encompass, e.g., an aqueous solution, or
gastrointestinal fluid.
[0047] By "sustained release" it is meant for purposes of the
invention that the therapeutically active medicament is released
from the formulation at a controlled rate such that therapeutically
beneficial blood levels (but below toxic levels) of the medicament
are maintained over an extended period of time, e.g., providing a
12 hour or a 24 hour dosage form.
[0048] By "bioavailable" it is meant for purposes of the invention
that the therapeutically active medicament is absorbed from the
formulation and becomes available in the body at the intended site
of drug action.
[0049] By "primary particle size" it is meant for purposes of the
invention that the particles are not agglomerated. Agglomeration is
common with respect to silicon dioxide particles, resulting in a
comparatively average large agglomerated particle size.
[0050] As one of ordinary skill in the art will appreciate, the
terms "microcrystalline cellulose in the form of a wet cake",
"hydrocellulose", and "hydrolyzed cellulose" are synonymous, and
refer to the precursor of the (dried) microcrystalline cellulose
product.
BRIEF DESCRIPTION OF THE DRAWINGS
[0051] The following drawings are illustrative of embodiments of
the invention and are not meant to limit the scope of the invention
as encompassed by the claims.
[0052] FIG. 1 graphically shows a comparison of the tensile
strength of tablets prepared in accordance with the invention and
prior art tablets.
[0053] FIG. 2 graphically shows a comparison of the tensile
strength of APAP containing tablets prepared in accordance with the
invention and prior art APAP containing tablets.
[0054] FIG. 3 graphically shows a comparison of the tensile
strength of tablets prepared in accordance with the invention to
contain MCC coprocessed with diatomaceous earth, tablets containing
MCC coprocessed with 2% w/w SiO.sub.2 and prior art tablets
prepared to contain only unmodified MCC.
[0055] FIG. 4 graphically illustrates a comparison of the tensile
strength of tablets prepared using MCC coprocessed with silica gel,
tablets prepared with the novel coprocessed MCC and tablets
prepared with MCC alone.
[0056] FIG. 5 graphically illustrates a comparison of the tensile
strength of tablets prepared using MCC coprocessed with SiO.sub.2,
and prior art tablets prepared to contain only unmodified MCC.
[0057] FIG. 6 graphically illustrates a comparison of the load vs.
deflection data for tablets compressed from coprocessed
MCC-SiO.sub.2 dried to an LOD of 0.9%, tablets compressed from
Emcocel.RTM. 90M dried to an LOD of 0.9%, and tablets compressed
from commercially available Emcocel.RTM. 90M.
[0058] FIG. 7 graphically illustrates a comparison of the load vs.
deflection data for tablets compressed from coprocessed
MCC-SiO.sub.2 dried to an LOD of 1.8%, and tablets compressed from
commercially available Emcocel.RTM. 90M having an LOD of 5.7%.
[0059] FIG. 8 graphically illustrates a comparison of the relative
density specific stress vs. strain data for tablets compressed from
coprocessed MCC-SiO.sub.2 dried to an LOD of 0.9%, tablets
compressed from Emcocel.RTM. 90M dried to an LOD of 0.9%, and
tablets compressed from commercially available Emcocel.RTM.
90M.
[0060] FIG. 9 is a table which compares the LOD, Density, Failure
Load, Deflection, and Energy of Failure of tablets compressed from
coprocessed MCC-SiO.sub.2 dried to an LOD of 0.9%, tablets
compressed from Emcocel.RTM. 90M dried to an LOD of 0.9%, tablets
compressed from commercially available Emcocel.RTM. 90M, tablets
compressed from commercially available Emcocel.RTM. XLM 90, and
tablets compressed from commercially available PROSOLV SMCC.RTM.
90.
[0061] FIG. 10 graphically illustrates a comparison of the density
specific stress vs. strain data for tablets compressed from
coprocessed MCC-SiO.sub.2 dried to an LOD of 0.9%, tablets
compressed from Emcocel.RTM. 90M dried to an LOD of 0.9%, tablets
compressed from commercially available Emcocel.RTM. 90M, tablets
compressed from commercially available Emcocel.RTM. XLM 90, tablets
compressed from commercially available PROSOLV SMCC.RTM. 90, and
tablets compressed from commercially available high density grade,
Emcocel.RTM. ID 90.
[0062] FIG. 11 graphically illustrates a comparison of the relative
density specific stress vs. strain data for tablets compressed from
coprocessed MCC-SiO.sub.2 dried to an LOD of 0.9%, tablets
compressed from Emcocel.RTM. 90M dried to an LOD of 0.9%, tablets
compressed from commercially available Emcocel.RTM. 90M, tablets
compressed from commercially available Emcocel.RTM. XLM 90, tablets
compressed from commercially available PROSOLV SMCC.RTM. 90, and
tablets compressed from commercially available Emcocel.RTM. HD
90.
DETAILED DESCRIPTION OF THE INVENTION
[0063] Microcrystalline cellulose is a well-known tablet diluent
and disintegrant. Its chief advantage over other excipients is that
it can be directly compressed into self-binding tablets which
disintegrate rapidly when placed into water. This widely-used
ingredient is prepared by partially depolymerizing cellulose
obtained as a pulp from fibrous plant material with dilute mineral
acid solutions. Following hydrolysis, the hydrocellulose thereby
obtained is purified via filtration and the aqueous slurry is spray
dried to form dry, white odorless, tasteless crystalline powder of
porous particles of a broad size distribution. In this regard, one
of ordinary skill in the art will appreciate that the terms
"hydrolyzed cellulose", "hydrocellulose", and "microcrystalline
cellulose in the form of a wet cake" are synonymous and encompass
materials prepared by partially depolymerizing cellulose obtained
as pulp. Another method of preparing microcrystalline cellulose is
disclosed in U.S. Pat. No. 3,141,875. This reference discloses
subjecting cellulose to the hydrolytic action of hydrochloric acid
at boiling temperatures' so that amorphous cellulosic material can
be removed and aggregates of crystalline cellulose are formed. The
aggregates are collected by filtration, washed with water and
aqueous ammonia and disintegrated into small fragments, often
called cellulose crystallites by vigorous mechanical means such as
a blender. Microcrystalline cellulose is commercially available in
several grades which range in average particle size from 20 to 200
microns.
[0064] Microcrystalline cellulose is water-insoluble, but the
material has the ability to draw fluid into a tablet by capillary
action. The tablets then swell on contact and the microcrystalline
cellulose thus acts as a disintegrating agent. The material has
sufficient self-lubricating qualities so as to allow a lower level
of lubricant as compared to other excipients.
[0065] Typically, microcrystalline cellulose has an apparent
density of about 0.28 g/cm.sup.3 and a tap density of about 0.43
g/cm.sup.3. Handbook of Pharmaceutical Excipients pages 53-55.
[0066] When utilized in pharmaceutical applications,
microcrystalline cellulose is typically used as a tablet
binder/diluent in wet granulation and direct compression
formulations in amounts of 5-3.0% of the formulation, or more.
However, it is known to use more or less microcrystalline cellulose
in pharmaceutical products, depending upon the requirements of the
formulation.
[0067] Silicon dioxide is obtained by insolubilizing dissolved
silica in sodium silicate solution. When obtained by the addition
of sodium silicate to a mineral acid, the product is termed silica
gel. When obtained by the destabilization of a solution of sodium
silicate in such a manner as to yield very fine particles, the
product is termed precipitated silica. Silicon dioxide is insoluble
in water. Prior to the present invention, silicon dioxide, and in
particular colloidal silicon dioxide, was used mainly as a glidant
and anti-adherent in tabletting processes and encapsulation,
promoting the flowability of the granulation. The amount of silicon
dioxide included in such tablets for those applications is very
limited, 0.1-0.5% by weight. Handbook of Pharmaceutical Excipients,
.COPYRGT.1986 American Pharmaceutical Association, page 255. This
is due in part to the fact that increasing the amount of silicon
dioxide in the mixture to be tabletted causes the mixture to flow
too well, causing a phenomena known to those skilled in the
tabletting art as "flooding". If the mixture flows too well, a
varying tablet weight with uneven content uniformity can
result.
[0068] Those skilled in the art will appreciate that the name
and/or method of preparation of the silicon dioxide utilized in the
present invention is not determinative of the usefulness' of the
product. Rather, as previously mentioned, it has been surprisingly
discovered that it is the physical characteristics of the silicon
dioxide which are critical. In particular, it has been discovered
that silicon dioxide having a relatively large particle size (and
correspondingly small surface area), such as silica gel, is not
useful in the preparation of the improved microcrystalline
cellulose products of the invention. The appended claims are deemed
to encompass all forms of silicon dioxide having an average primary
particle size from about 1 nm to about 100 .mu.m, and/or a surface
area from about 10 m.sup.2/g to about 500 m.sup.2/g.
[0069] The silicon dioxide utilized in the invention is of the very
fine particle size variety. In the most preferred embodiments of
the invention, the silicon dioxide utilized is a colloidal silicon
dioxide. Colloidal silicon dioxide is a submicron fumed silica
prepared by the vapor-phase hydrolysis (e.g., at 1110.degree. C.)
of a silicon compound, such as silicon tetrachloride. The product
itself is a submicron, fluffy, light, loose, bluish-white, odorless
and tasteless amorphous powder which is commercially available from
a number of sources, including Cabot Corporation (under the
tradename Cab-O-Sil); Degussa, Inc. (under the tradename Aerosil);
and E.I. DuPont & Co. Colloidal silicon dioxide is also known
as colloidal silica, fumed silica, light anhydrous silicic acid,
silicic anhydride, and silicon dioxide fumed, among others. A
variety of commercial grades of colloidal silicon dioxide are
produced by varying the manufacturing process. These modifications
do not affect the silica content, specific gravity, refractive
index, color or amorphous form. However, these modifications are
known to change the particle size, surface areas, and bulk
densities of the colloidal silicon dioxide products.
[0070] The surface area of the preferred class of silicon dioxides
utilized in the invention ranges from about 50 m.sup.2/gm to about
500 m.sup.2/gm. The average primary particle diameter of the
preferred class of silicon dioxides utilized in the invention
ranges from about 5 nm to about 50 nm. However, in commercial
colloidal silicon dioxide products, these particles are
agglomerated or aggregated to varying extents. The bulk density of
the preferred class of silicon dioxides utilized in the invention
ranges from about 20 g/l to about 100 Commercially available
colloidal silicon dioxide products have, for example, a BET surface
area ranging from about 50.+-.15 m.sup.2/gm (Aerosil OX50) to about
400.+-.20 (Cab-O-Sil S-17) or 390.+-.40 m.sup.2/gm (Cab-O-Sil
EH-5). Commercially available particle sizes range from a nominal
particle diameter of 7 nm (e.g., Cab-O-Sil S-17 or Cab-O-Sil EH-5)
to an average primary particle size of 40 nm (Aerosil OX50). The
density of these products range from 72.0.+-.8 g/l (Cab-O-Sil S-17)
to 36.8 g/l (e.g., Cab-O-Sil M-5). The pH of the these products at
4% aqueous dispersion ranges from pH 3.5-4.5. These commercially
available products are described for exemplification purposes of
acceptable properties of the preferred class of silicon dioxides
only, and this description is not meant to limit the scope of the
invention in any manner whatsoever.
[0071] When the novel excipient of the invention utilizes a
colloidal silicon dioxide, it has been found that the resultant
excipient product surprisingly provides a compressibility which is
substantially improved in preferred embodiments even in comparison
to the compressibility of normal "off-the-shelf" commercially
available microcrystaline cellulose used in direct compression
techniques.
[0072] In other embodiments of the present invention, it has been
discovered that the compressibility of microcrystalline cellulose
which is wet granulated is significantly improved by a wider range
of silicon dioxide products. Thus, in embodiments of the present
invention where an improvement in overall compressibility of the
microcrystalline cellulose (whether utilized in wet granulation or
dry granulation) is not important, and the microcrystalline
cellulose product is to be subjected to wet granulation, it has
been discovered that the surface area of the silicon dioxide can be
as low as about 50 m.sup.2/gm and the average primary particle
diameter can be as large as about 100 .mu.m. Such silicon dioxide
products are also deemed to be encompassed within the scope of the
invention.
[0073] Both microcrystalline cellulose in the form of a wet cake
(i.e hydrolyzed cellulose or hydrocellulose) and silicon dioxide
are substantially water insoluble. Therefore, the particle size of
these ingredients as present in the well-dispersed aqueous slurry
is directly related to the particle size of these two ingredients
as they were introduced into the aqueous solution. There is no
appreciable dissolution of either ingredient in the aqueous
slurry.
[0074] After a uniform mixture of the ingredients is obtained in
the suspension, the suspension is dried to provide a plurality of
microcrystalline cellulose-based excipient particles having
enhanced compressibility.
[0075] In the spray-drying process, the aqueous dispersion of
microcrystalline cellulose in the form of a wet cake and silicon
dioxide is brought together with a sufficient volume of hot air to
produce evaporation and drying of the liquid droplets. The highly
dispersed slurry of microcrystalline cellulose in the form of a wet
cake and silicon dioxide is pumpable and capable of being atomized.
It is sprayed into a current of warm filtered air, which supplies
the heat for evaporation and conveys a dried product to a
collecting device. The air is then exhausted with the removed
moisture. The resultant spray-dried powder particles are
approximately spherical in shape and are relatively uniform in
size, thereby possessing excellent flowability. The coprocessed
product consists of microcrystalline cellulose and silicon dioxide
in intimate association with each other. Magnifications of the
resultant particles indicate that the silicon dioxide is integrated
with, or partially coats, the surfaces of the microcrystalline
cellulose particles. When the amount of silicon dioxide included in
the excipient is greater than about 20% by weight relative to the
microcrystalline cellulose, the silicon dioxide appears to
substantially coat the surfaces of the microcrystalline cellulose
particles. The exact relationship of the two ingredients of the
excipients after coprocessing is not presently understood; however,
for purposes of description the coprocessed particles are described
herein as including an agglomerate of microcrystalline cellulose
and silicon dioxide in intimate association with each other. By
"intimate association", it is meant that the silicon dioxide has in
some manner been integrated with the microcrystalline cellulose
particles, e.g., via a partial coating of the microcrystalline
particles, as opposed to a chemical interaction of the two
ingredients.
[0076] The term "intimate association" is therefore deemed for
purposes of the present description as being synonymous with
"integrated" or "united". The coprocessed particles are not
necessarily uniform or homogeneous. Rather, under magnification,
e.g., scanning electron microscope at 500.times., the silicon
dioxide at the preferred percent inclusion appears to be an
"edge-coating".
[0077] It is most preferred in the present invention that the
microcrystalline cellulose and silicon dioxide are coprocessed,
resulting in an intimate association of these ingredients, rather
than being combined, e.g., as a dry mixture. In preferred
embodiments of the present invention, the aqueous slurry of the
microcrystalline cellulose in the form of a wet cake and silicon
dioxide are introduced into the spray dryer as a single aqueous
medium. However, it is possible to separately introduce each
ingredient into separate aqueous medium which are then combined.
Other procedures for combining the microcrystalline cellulose in
the form of a wet cake (i.e. hydrocellulose or hydrolyzed
cellulose) and silicon dioxide known to those skilled in the art
are deemed to be equivalent to the spray-drying technique described
above, and are further deemed to be encompassed by the appended
claims.
[0078] In certain preferred embodiments of the present invention,
the coprocessing of the microcrystalline cellulose and silicon
dioxide is accomplished by forming a well-dispersed aqueous slurry
of microcrystalline cellulose in the form of a wet cake and silicon
dioxide, and thereafter drying the slurry and forming a plurality
of microcrystalline cellulose-based excipient particles. Typically,
microcrystalline cellulose in the form of a wet cake is first added
to an aqueous solution so that a slurry or suspension containing
from about 0.5% to about 25% microcrystalline cellulose in the form
of solids is obtained. Preferably, the slurry or suspension
contains from about 15% to 20% microcrystalline cellulose in the
form of a wet cake and most preferably from about 17% to about 19%
microcrystalline cellulose in the form of a wet cake. At this
stage, it is often desirable to adjust the pH of the slurry to
about neutral with ammonium hydroxide, sodium hydroxide, and
mixtures thereof or the like. The suspension is kept under constant
agitation for a sufficient time to assure a uniform distribution of
the solids prior to being combined with the silicon dioxide.
[0079] At this point, the silicon dioxide is added to the
suspension or slurry in amounts ranging from 0.1% to about 20% by
weight, based on the amount of microcrystalline cellulose, amounts
from about 0.5% to about 10% are preferred while amounts of from
about 1.25% to about 5% by weight are especially preferred. The
silicon dioxide is preferably in colloidal form prior to addition
to the slurry. The microcrystalline cellulose in the form of a wet
cake and colloidal silicon dioxide are well-dispersed in the slurry
or suspension prior drying and forming the novel particles.
[0080] It is preferred that the suspension be dried using
spray-drying techniques, as they are known in the art. Other drying
techniques, however, such as flash drying, ring drying, micron
drying, tray drying, vacuum drying, radio-frequency drying, and
possibly microwave drying, can also be used. The exact manner in
which the suspension is dried is not believed to be critical for
the microcrystalline cellulose/silicon dioxide particles to
demonstrate enhanced compressibility after wet granulating.
[0081] Depending upon the amount and type of drying, the
concentration of the microcrystalline cellulose in the form of a
wet cake and silicon dioxide in the suspension, the novel
compressible particles will have different particle sizes,
densities, pH, moisture content, etc.
[0082] The particulate coprocessed product of the present invention
possesses desirable performance attributes that are not present
when the combination of microcrystalline cellulose and silicon
dioxide are combined as a dry mixture. It is believed that the
beneficial result obtained by the combination of these two
materials is due to the fact that the two materials are intimately
associated with each other.
[0083] The average particle size of the integrated excipient of the
present invention ranges from about 10 microns to about 1000
microns. Particle sizes of about 10-500 microns are preferred,
particle sizes of about 30-250 microns are more preferred and
particle sizes of about 40-200 microns are most preferred. It will
be appreciated by those of ordinary skill in the art that the
drying of the microcrystalline cellulose in the form of a wet
cake-silicon dioxide suspension results in a random size
distribution of the novel excipient particles being produced. For
example if spray drying techniques are used, droplet size,
temperatures, agitation, dispersion, air flow, atomizer wheel
speed, etc. will effect final particle size. Furthermore, it is
within the scope of the invention to sort or mechanically alter the
dried particles according to ranges of particle sizes depending
upon end uses. The particle size of the integrated excipient is not
narrowly critical, the important parameter being that the average
size of the particle must permit the formation of a directly
compressible excipient which forms pharmaceutically acceptable
tablets.
[0084] The novel excipient has a bulk (loose) density ranging from
about 0.2 g/ml to about 0.6 g/ml, and most preferably from about
0.35 g/ml to about 0.55 g/ml. The novel excipient has a tapped
density ranging from about 0.2 g/ml to about 0.6 g/ml, and most
preferably from about 0.35 g/ml to about 0.55 g/ml. The pH of the
particles is most preferably about neutral, although granulates
having a pH of from about 3.0 to about 8.5 are possible. The
moisture content of the excipient particles will broadly range from
about 0.5% to about 15%, preferably from about 2.5% to about 6%,
and most preferably from about 3.0% to about 5% by weight.
[0085] The angle of repose is a measurement used to determine the
flow characteristics of a powder. The angle of repose is subject to
experiment and experimenter, but in a comparative test, the novel
excipient is superior.
[0086] As set forth above, in accordance with another embodiment of
the present invention, the novel excipient is an extra low moisture
excipient which comprises a particulate agglomerate of coprocessed
microcrystalline cellulose and from about 0.1% to about 20% silicon
dioxide, by weight of the microcrystalline cellulose, the
microcrystalline cellulose and silicon dioxide being in intimate
association with each other, and the silicon dioxide portion of the
agglomerate being derived from a silicon dioxide having a particle
size from about 1 nanometer (nm) to about 100 microns (.mu.m),
based on average primary particle size, the excipient having a
moisture content of from about 0.5 to 2.5% LOD, preferably between
about 0.5 and about 1.8% LOD, more preferably between 0.8 and 1.5%
LOD, and most preferably between about 0.8 and about 1.2% LOD. The
excipient in accordance with this embodiment is particularly
suitable for use with moisture sensitive drugs because of its
relatively low moisture content. In fact, the extra low moisture
excipient in accordance with the invention exhibits a similar
compressibility to conventional microcrystalline cellulose products
having moisture content of 5-6% (such as Emcocel.RTM. 90M), and
superior compressibility to conventional extra low moisture
microcrytalline cellulose products (such as Emcocel.RTM. XLM 90)
having moisture 0.15 contents of about 1.2%. Moreover, it is
believed that the extra low moisture excipient in accordance with
the invention, when directly compressed or dry granulated with a
moisture sensitive drug, provides a drug product which is at least
as stable as drug products made with conventional extra low
moisture microcrystalline cellulose, while providing improved
compressibility. As explained above, when directly compressing an
active ingredient with an excipient such as microcrystalline
cellulose, the compressibility of the excipient is an important
consideration because use of a more compressible excipient provides
harder, more robust tablets, facilitates compaction of poorly
compactable actives, and allows for less excipient resulting in
smaller tablets.
[0087] The extra low moisture excipient is preferably prepared by
forming an aqueous slurry containing a mixture of microcrystalline
cellulose in the form of a wet cake (i.e. hydrocellulose or
hydrolyzed cellulose) and silicon dioxide having a particle size
from about 1 nm to about 100 .mu.m, and drying the slurry to obtain
microcrystalline cellulose-based excipient particles which have a
moisture content of from about 0.5 to 2.5% LOD, preferably between
about 0.5 and about 1.8% LOD, more preferably between 0.8 and 1.5%
LOD, and most preferably between about 0.8 and about 1.2% LOD, and
in which the silicon dioxide particles have been integrated with
the microcrystalline cellulose particles. As with the embodiments
discussed above, it is preferred that the suspension be dried using
spray-drying techniques. Other drying techniques, however, such as
flash drying, fluidized bed drying, ring drying, micron drying,
tray drying, vacuum drying, radio-frequency drying, and possibly
microwave drying, can also be used singly or in combination.
[0088] The novel excipient in accordance with the invention is
free-flowing and directly compressible. Accordingly, the excipient
may be mixed in the desired proportion with an active agent and
optional lubricant (blended or dry granulated), and then directly
compressed into solid dosage forms. In preferred embodiments of the
present invention wherein the silicon dioxide is colloidal silicon
dioxide, the novel excipient comprising the coprocessed
microcrystalline cellulose and colloidal silicon dioxide integrated
together represents an augmented microcrystalline cellulose having
improved compressibility as compared to standard commercially
available grades of microcrystalline cellulose.
[0089] Alternatively, all or part of the excipient may be subjected
to a wet granulation with the active ingredient. A representative
wet granulation includes loading the novel excipient particles into
a suitable granulator, such as those available from Baker-Perkins,
and granulating the particles together with the active ingredient,
preferably using an aqueous granulating liquid. The granulating
liquid is added to the mixture with stirring until the powdery mass
has the consistency of damp snow and then wet screened through a
desired mesh screen, for example, having a mesh from about 12 to
about 16. The screened granulate is then dried, using standard
drying apparatus such as a convection oven before undergoing a
final screening. Additional dry screening of this material is
possible, such as by using screens of from about 40 to about 200
mesh. Those materials flowing through 40 and 60 mesh screens may be
further ground prior to ultimate tablet formulation. The thus
obtained wet granulate containing novel excipient is now capable of
undergoing tabletting or otherwise placed into a unit dosage
form.
[0090] In certain preferred embodiments, a portion of the total
amount of the novel excipient is wet granulated with the active
ingredient, and thereafter the additional portion of the novel
excipient is added to the granulate. In yet other embodiments, the
additional portion of the novel excipient to be added to the
excipient/active ingredient granulate may be substituted with
conventional microcrystalline cellulose, or other excipients
commonly used by those skilled in the art, depending of course upon
the requirements of the particular formulation.
[0091] By virtue of the novel excipient of the present invention,
the amount of the novel excipient compared to the amount of
microcrystalline cellulose which must be used in a wet granulation
technique to obtain an acceptable solid dosage form is
substantially reduced.
[0092] In other embodiments of the invention, a further material is
added to the slurry of microcrystalline cellulose in the form of a
wet cake and silicon dioxide. Such additional materials include
non-silicon metal oxides, starches, starch derivatives,
surfactants, polyalkylene oxides, cellulose ethers, celluloses
esters and mixtures thereof. These additives may be included in
desired amounts which will be apparent to those skilled in the
art.
[0093] In addition to one or more active ingredients, additional
pharmaceutically acceptable excipients (in the case of
pharmaceuticals) or other additives known to those skilled in the
art (for non-pharmaceutical applications) can be added to the novel
excipient prior to preparation of the final product. For example,
if desired, any generally accepted soluble or insoluble inert
pharmaceutical filler (diluent) material can be included in the
final product (e.g., a solid dosage form). Preferably, the inert
pharmaceutical filler comprises a monosaccharide, a disaccharide, a
polyhydric alcohol, inorganic phosphates, sulfates or carbonates,
and/or mixtures thereof. Examples of suitable inert pharmaceutical
fillers include sucrose, dextrose, lactose, xylitol, fructose,
sorbitol, calcium phosphate, calcium sulfate, calcium carbonate,
"off-the-shelf" microcrystalline cellulose, mixtures thereof, and
the like.
[0094] An effective amount of any generally accepted pharmaceutical
lubricant, including the calcium or magnesium soaps may optionally
be added to the novel excipient at the time the medicament is
added, or in any event prior to compression into a solid dosage
form. The lubricant may comprise, for example, magnesium stearate
in any amount of about 0.5-3% by weight of the solid dosage
form.
[0095] The complete mixture, in an amount sufficient to make a
uniform batch of tablets, may then subjected to tabletting in a
conventional production scale tabletting machine at normal
compression pressures for that machine, e.g., about 1500-10,000
lbs/sq in. The mixture should not be compressed to such a degree
that there is subsequent difficulty in its hydration when exposed
to gastric fluid.
[0096] The average tablet size for round tablets is preferably
about 50 mg to 500 mg and for capsule-shaped tablets about 200 mg
to 2000 mg. However, other formulations prepared in accordance with
the present invention may be suitably shaped for other uses or
locations, such as other body cavities, e.g., periodontal pockets,
surgical wounds, vaginally. It is contemplated that for certain
uses, e.g., antacid tablets, vaginal tablets and possibly implants,
that the tablet will be larger.
[0097] In certain embodiments of the invention, the tablet is
coated with a sufficient amount of a hydrophobic polymer to render
the formulation capable of providing a release of the medicament
such that a 12 or 24 hour formulation is obtained. The hydrophobic
polymer which included in the tablet coating may be the same or
different material as compared to the hydrophobic polymeric
material which is optionally granulated with the sustained release
excipient. In other embodiments of the present invention, the
tablet coating may comprise an enteric coating material in addition
to or instead or the hydrophobic polymer coating. Examples of
suitable enteric polymers include cellulose acetate phthalate,
hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate,
methacrylic acid copolymer, shellac, hydroxypropylmethylcellulose
succinate, cellulose acetate trimellitate, and mixtures of any of
the foregoing. An example of a suitable commercially available
enteric material is available under the trade name Eudragit.TM. L
100-555.
[0098] In further embodiments, the dosage form may be coated with a
hydrophilic coating in addition to or instead of the
above-mentioned coatings. An example of a suitable material which
may be used for such a hydrophilic coating is
hydroxypropylmethylcellulose (e.g., Opadry.RTM., commercially
available from Colorcon, West Point, Pa.).
[0099] The coatings may be applied in any pharmaceutically
acceptable manner known to those skilled in the art. For example,
in one embodiment, the coating is applied via a fluidized bed or in
a coating pan. For example, the coated tablets may be dried, e.g.,
at about 60-70.degree. C. for about 3-4 hours in a coating pan. The
solvent for the hydrophobic polymer or enteric coating may be
organic, aqueous, or a mixture of an organic and an aqueous
solvent. The organic solvents may be, e.g., isopropyl alcohol,
ethanol, and the like, with or without water.
[0100] The coatings which may be optionally applied to the
compressed solid dosage form of the invention may comprise from
about 0.5% to about 30% by weight of the final solid dosage
form.
[0101] In additional embodiments of the present invention, a
support platform is applied to the tablets manufactured in
accordance with the present invention. Suitable support platforms
are well known to those skilled in the art. An example of suitable
support platforms is set forth, e.g., in U.S. Pat. No. 4,839,177,
hereby incorporated by reference. In that patent, the support
platform partially coats the tablet, and consists of a polymeric
material insoluble in aqueous liquids. The support platform may,
for example, be designed to maintain its impermeability
characteristics during the transfer of the therapeutically active
medicament. The support platform may be applied to the tablets,
e.g., via compression coating onto part of the tablet surface, by
spray coating the polymeric materials comprising the support
platform onto all or part of the tablet surface, or by immersing
the tablets in a solution of the polymeric materials.
[0102] The support platform may have a thickness of, e.g., about 2
mm if applied by compression, and about 10 .mu.m if applied via
spray-coating or immersion-coating. Generally, in embodiments of
the invention wherein a hydrophobic polymer or enteric coating is
applied to the tablets, the tablets are coated to a weight gain
from about 1% to about 20%, and in certain embodiments preferably
from about 5% to about 10%.
[0103] Materials useful in the hydrophobic coatings and support
platforms of the present invention include derivatives of acrylic
acid (such as esters of acrylic acid, methacrylic acid, and
copolymers thereof) celluloses and derivatives thereof (such as
ethylcellulose), polyvinylalcohols, and the like.
[0104] In certain embodiments of the present invention, the tablet
core includes an additional dose of the medicament included in
either the hydrophobic or enteric coating, or in an additional
overcoating coated on the outer surface of the tablet core (without
the hydrophobic or enteric coating) or as a second coating layer
coated on the surface of the base coating comprising the
hydrophobic or enteric coating material. This may be desired when,
for example, a loading dose of a therapeutically active agent is
needed to provide therapeutically effective blood levels of the
active agent when the formulation is first exposed to gastric
fluid. The loading dose of medicament included in the coating layer
may be, e.g., from about 10% to about 40% of the total amount of
medicament included in the formulation.
[0105] The active agent(s) which may be incorporated with the novel
excipient described herein into solid dosage forms invention
include systemically active therapeutic agents, locally active
therapeutic agents, disinfecting agents, chemical impregnants,
cleansing agents, deodorants, fragrances, dyes, animal repellents,
insect repellents, a fertilizing agents, pesticides, herbicides,
fungicides, and plant growth stimulants, and the like.
[0106] A wide variety of therapeutically active agents can be used
in conjunction with the present invention. The therapeutically
active agents (e.g. pharmaceutical agents) which may be used in the
compositions of the present invention include both water soluble
and water insoluble drugs. Examples of such therapeutically active
agents include antihistamines (e.g., dimenhydrinate,
diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate),
analgesics (e.g., aspirin, codeine, morphine, dihydromorphone,
oxycodone, etc.), non-steroidal anti-inflammatory agents (e.g.,
naproxyn, diclofenac, indomethacin, ibuprofen, sulindac),
anti-emetics (e.g., metoclopramide), anti-epileptics (e.g.,
phenyloin, meprobamate and nitrezepam), vasodilators (e.g.,
nifedipine, papaverine, diltiazem and nicardirine), anti-tussive
agents and expectorants (e.g., codeine phosphate), anti-asthmatics
(e.g. theophylline), antacids, anti-spasmodics (e.g. atropine,
scopolamine), antidiabetics (e.g., insulin), diuretics (e.g.,
ethacrynic acid, bendrofluazide), anti-hypotensives (e.g.,
propranolol, clonidine), antihypertensives (e.g, clonidine,
methyldopa), bronchodilators (e.g., albuterol), steroids (e.g.,
hydrocortisone, triamcinolone, prednisone), antibiotics (e.g.,
tetracycline), antihemorrhoidals, hypnotics, psychotropics,
antidiarrheals, mucolytics, sedatives, decongestants, laxatives,
vitamins, stimulants (including appetite suppressants such as
phenylpropanolamine). The above list is not meant to be
exclusive.
[0107] A wide variety of locally active agents can be used in
conjunction with the novel excipient described herein, and include
both water soluble and water insoluble agents. The locally active
agent(s) which may be included in the controlled release
formulation of the present invention is intended to exert its
effect in the environment of use, e.g., the oral cavity, although
in some instances the active agent may also have systemic activity
via absorption into the blood via the surrounding mucosa.
[0108] The locally active agent(s) include antifungal agents (e.g.,
amphotericin B, clotrimazole, nystatin, ketoconazole, miconazol,
etc.), antibiotic agents (penicillins, cephalosporins,
erythromycin, tetracycline, aminoglycosides, etc.), antiviral
agents (e.g, acyclovir, idoxuridine, etc.), breath fresheners (e.g.
chlorophyll), antitussive agents (e.g., dextromethorphan
hydrochloride), anti-cariogenic compounds (e.g., metallic salts of
fluoride, sodium monofluorophosphate, stannous fluoride, amine
fluorides), analgesic agents (e.g., methylsalicylate, salicylic
acid, etc.), local anesthetics (e.g., benzocaine), oral antiseptics
(e.g., chlorhexidine and salts thereof, hexylresorcinol,
dequalinium chloride, cetylpyridinium chloride), anti-flammatory
agents (e.g., dexamethasone, beta-methasone, prednisone,
prednisolonc, triamcinolone, hydrocortisone, etc.), hormonal agents
(oestriol), antiplaque agents (e.g, chlorhexidine and salts
thereof, octenidine, and mixtures of thymol, menthol,
methysalicylate, eucalyptol), acidity reducing agents (e.g.,
buffering agents such as potassium phosphate dibasic, calcium
carbonate, sodium bicarbonate, sodium and potassium hydroxide,
etc.), and tooth desensitizers (e.g., potassium nitrate). This list
is not meant to be exclusive. The solid formulations of the
invention may also include other locally active agents, such as
flavorants and sweeteners. Generally any flavoring or food additive
such as those described in Chemicals Used in Food Processing, pub
1274 by the National Academy of Sciences, pages 63-258 may be used.
Generally, the final product may include from about 0.1% to about
5% by weight flavorant.
[0109] As set forth above, the extra low moisture co-processed
MCC-SiO.sub.2 excipient in accordance with the present invention is
particularly useful in the tableting of moisture sensitive drugs.
As used herein "moisture sensitive drugs" are defined as drugs
which exhibit decreased stability when exposed to moisture. The
moisture sensitivity of a drug can be determined by placing the
drug in open dishes at relative humidities of 30 to 90%, and
monitoring the samples regularly for physical changes, water
content, and chemical degradation. See Lachmen et al, THE THEORY
AND PRACTICE OF INDUSTRIAL PHARMACY 21-22 (1976). When tableting a
moisture sensitive drug, it is important that the excipient used
have a low moisture content so that the amount of moisture
contributed to the tablet by the excipient is minimized. Examples
of moisture sensitive drugs include which may be utilized with the
extra low moisture excipient in accordance with the present
invention include: acetysalicylic acid, aminophylline, ascorbic
acid,
[0110] atenolol, betahistine mesylate, calcium chloride, captopril,
carbachol, carpronium chloride, cefaclor, cefadroxil, cephrabine,
chlorophyllin sodium-copper salt, choline salicylate, choline
theophyllinate, citicoline, clindamycin HCl, cyanocobalamin,
desipramine HCl, dexamethazone phosphate disodium salt, diclofenac
sodium, dimethylaminoethyl ester dihydrochloride, disopyramide
phosphate, divalproex sodium, ethionamide, fenoprofen calcium,
gemfibrozil, hexamethonium bromide, isosorbide, L-proline
meprobamate, methocarbamol, methyldopa, oxtriphylline,
oxytetracycline HCl, panthenol, piracetam, plant extracts (Querci
Folium extract, Mallot Cortex extract, Equisetum arvense extract,
etc.), procainamide HCl, procainamide hydrochloride, ranitine HCl,
reserpilic acid, rifamprin, lincomycin HCl, sodium valproate,
tetracycline HCl, thiamine Hcl, clavlenic acid and salts thereof,
polymixin, herbals, herbal extracts, nutritional products,
nitroglycerin, alkaloid salts, streptomycin, idoxuridine, and
tolazoline hydrochloride.
[0111] The tablets of the present invention may also contain
effective amounts of coloring agents, (e.g., titanium dioxide, F.D.
& C. and D. & C. dyes; see the Kirk-Othmer Encyclopedia of
Chemical Technology, Vol. 5, pp. 857-884, hereby incorporated by
reference), stabilizers, binders, odor controlling agents, and
preservatives.
[0112] Alternatively, the novel excipient can be utilized in other
applications wherein it is not compressed. For example, the
granulate can be admixed with an active ingredient and the mixture
then filled into capsules. The granulate can further be molded into
shapes other than those typically associated with tablets. For
example, the granulate together with active ingredient can be
molded to "fit" into a particular area in an environment of use
(e.g., an implant). All such uses would be contemplated by those
skilled in the art and are deemed to be encompassed within the
scope of the appended claims.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0113] The following examples illustrate various aspects of the
present invention. They are not to be construed to limit the claims
in any manner whatsoever.
[0114] The examples set forth the preparation of various
microcrystalline cellulose/silicon dioxide compositions. Tablets
were prepared using each of the compositions and each of tablet
preparations was tested for tensile strength.
EXAMPLES 1-3
Preparation of Coprocessed MCC-SiO.sub.2 Compositions and
Granulations Thereof
Example 1
MCC-SiO.sub.2 Product-5% w/w SiO.sub.2
[0115] A. Excipient Particles
[0116] In this example, about 6.2 kilograms of microcrystalline
cellulose (MCC), (Mendell Co., Inc. Patterson, N.Y.) in the form of
a wet cake (i.e., hydrocellulose or hydrolyzed cellulose) was
combined with 5.2 kilograms of water in a mix tank to form a slurry
containing about 15% solids. The pH was adjusted to about neutral
with about 3 ml of ammonium hydroxide. The slurry was allowed to
mix for about 15 minutes before being combined with 5% w/w silicon
dioxide (SiO), 200 m.sup.2/g (CaboSil, PTG grade, available from
Cabot Corp., Tuscola, Ill.) After allowing the materials to become
intimately combined, the slurry was spray dried using a Niro
Production Minor (Niro, Columbia, Md.), inlet
temperature-215.degree. C., outlet temperature-125.degree. C.,
atomizer wheel speed 22,300 rpm, to provide MCC-SiO.sub.2 having an
average particle size of 40-60 microns.
[0117] B. Granulation of Excipient Particles
[0118] The MCC-SiO.sub.2 particles obtained as a result of Example
1A. were wet granulated in a Baker-Perkins 10 liter high-sheer
granulator for 3 minutes using water as the granulating fluid. The
resultant product was wet screened through a 12 mesh screen, tray
dried in a convection oven for about 2-3 hours until a moisture
content of less than 5% was obtained, dry screened and sieved to
obtain an average particle size of from about 55 to about 70
mucrons.
Example 2
MCC-SiO.sub.2 Product-20% w/w SiO.sub.2
[0119] The processes of Example 1A and B were repeated except that
20% w/w silicon dioxide was used to form the product.
Example 3
MCC-SiO.sub.2 Product-2% w/w SiO.sub.2
[0120] In this example, the processes of Example 1A and B were
repeated except that 2% w/w silicon dioxide was used to form the
product.
EXAMPLE 4
Dry Blend Mix of MCC and SiO.sub.2 (5% w/w)--Comparative
[0121] As a control, EMCOCEL.RTM. grade 50 M microcrystalline
cellulose (Mendell Co., Inc.) and 5% w/w silicon dioxide, 200
m.sup.2/g (CaboSil, PTG grade) were dry blended. No spray drying or
other treatment of the mixture was undertaken. The method of
Example 1B, however, was repeated.
EXAMPLE 5
Processed MCC without SiO.sub.2
[0122] As a second control, the process described in Example 1B was
repeated except that no SiO.sub.2 was added.
EXAMPLE 6
[0123] In this example, batches of compressed tablets were prepared
using each of the products obtained as a result of Examples 1-5.
The tablets were prepared using a Korsch tablet press having a
punch size of 3/8" and an aim weight of about 245 mg. The
granulations were included in five separate tabletting runs using
compression forces of 6, 12, 18, 24 and 30 kN respectively. Ten
tablets from each run were weighed, measured for diameter and
tested for thickness and hardness on the Erweka TBH 30 tablet
hardness tester to determine the compressibility of the
microcrystalline cellulose as measured by tensile strength. The
results of the analysis are graphically illustrated in FIG. 1 as a
comparison of tensile strength versus compression force.
[0124] As can be seen from the graph, substantial benefits are
obtained by coprocessing MCC with SiO.sub.2. The tablets prepared
using the products of comparative examples 4 and 5 demonstrated
poor tensile strength. The novel excipient is superior and
demonstrates approximately the same relative improvement across the
entire range of compression forces. Furthermore, the graph also
illustrates that tablets prepared with a mere dry admixture of MCC
and SiO.sub.2 (example 4 formulation) failed to demonstrate
acceptable tensile strengths. Thus, the coprocessed MCC-SiO.sub.2
described herein provides significant retention of MCC
compressibility.
EXAMPLES 7-12
[0125] In these examples, compressed tablet products containing 70%
by weight MCC and 30% acetaminophen (APAP herein) were prepared.
The products of examples 7-9 were controls and prepared without the
coprocessed MCC-SiO.sub.2 of the present invention. The products of
examples 10-12, on the other hand, included 70% by weight of the
novel co-processed MCC-SiO.sub.2 and 30% APAP. Details concerning
the preparation of each granulation product is set forth below. A
graphical comparison of the tensile strength versus compression
force for each tabletted product is provided in FIG. 2.
Example 7
Intragranulation and Extragranulation of APAP with MCC
[0126] In this example, tablets were prepared using off-the-shelf
MCC (EMCOCEL.RTM. 50 M) according to the following formula:
1 INGREDIENTS WEIGHT (GRAMS) MCC 267.9 APAP 114.8 Deionized water
165.8
[0127] One half of the MCC was added to a Baker-Perkins 10 liter
blender and combined with all of the APAP. The blender impeller was
adjusted to 200 rpm and the chopper was set at 1000 rpm. After one
minute, the water was added over 90 seconds using a rinse bottle.
Thereafter, mixing was continued for an additional 90 seconds. The
granulation was removed from the blender, wet screened through a 12
screen mesh and dried in a convection oven for 2-3 hours at
60.degree. C. until a moisture content of less than 5% was
obtained. The granulation was then dry screened through a 16 mesh
screen before being blended for 10 minutes with the remaining
portion of the MCC in a 2 quart V-blender. The granulation was
removed from the blender and tabletted in accordance with the
method described below.
Tablet Strength Testing
[0128] In order to prepare tablets for the formulations of examples
7, 8, 10 and 11, the following procedure was used. The wet
granulation products were weighed and mixed in a 2 quart V-blender
for 5 minutes with 0.2% Pruv.TM. (sodium stearyl fumarate,
available from Mendell Co., Inc.). Five separate tabletting runs
were undertaken with compression forces of 5, 10, 15, 20 and 25 kN
respectively using a Korsch tablet press having a punch size of
3/8" and an aim weight of about 245 mg. Ten tablets from each
compression force were selected and used in the experiment set
forth in Example 13.
Example 8
Wet Granulation of APAP with MCC
[0129] In this example, only wet granulation or the
intragranulation step as described above was undertaken. The
formulation was prepared according to the following formula using
off-the-shelf EMCOCEL.RTM. 50 M MCC:
2 INGREDIENTS WEIGHT (GRAMS) MCC 178.6 APAP 76.5 Deionized water
170.1
[0130] The MCC was added to a Baker-Perkins 10 liter blender and
combined with the APAP. The blender impeller was adjusted to 200
rpm and the chopper was set at 1000 rpm. After one minute, the
water was added over 90 seconds using a rinse bottle. Thereafter,
mixing was continued for an additional 90 seconds. The granulation
was removed from the blender, wet screened through a 12 screen mesh
and then dried in a convection oven at 60.degree. C. for 2-3 hours,
until a moisture content of less than 5% was achieved. The
granulation was then dry screened through a 16 mesh screen and
tabletted in accordance with the method described in example 7.
Example 9
Direct Compression Formulation of APAP with MCC
[0131] A direct compression formulation for tablets was prepared to
contain 70% off-the-shelf EMCOCEL.RTM. 50 M MCC and 30% APAP by
weight. The tablets were prepared according to the following
formula:
3 INGREDIENTS WEIGHT (GRAMS) MCC 175.0 APAP 74.5 PRUV 0.5
[0132] The MCC and APAP were combined in a V-blender and mixed for
15 minutes. Thereafter, the Pruv was added and mixing was continued
for another 5 minutes. The granulation was removed and five
separate tabletting runs were undertaken using compression forces
of 5, 10, 15, 20 and 25 kN respectively on a Korsch tablet press.
The tablet press had a punch size of 3/8" and an aim weight of
about 245 mg. Ten tablets from each compression force were used in
the experiment set forth in Example 13.
EXAMPLE 10
Wet Granulation of APAP with Coprocessed MCC-SiO.sub.2 (5% w/w)
[0133] In this example, tablets were prepared by wet granulation
with the coprocessed MCC (5% w/w SiO.sub.2) of Example 1A. The
tablet granulation was prepared according to the following
formula:
4 INGREDIENTS WEIGHT (GRAMS) MCC-SiO.sub.2 178.6 APAP 76.5
Deionized water 170.1
[0134] The MCC-SiO.sub.2 was added to a Baker-Perkins 10 liter
blender and combined with the APAP. The blender impeller was
adjusted to 200 rpm and the chopper was set at 1000 rpm. After one
minute, the water was added over 90 seconds using a rinse bottle.
Thereafter, mixing was continued for an additional 90 seconds. The
granulation was removed from the blender, wet screened through a 12
screen mesh and then dried in a convection oven for 2-3 hours at
60.degree. C. until a moisture content of less than 5% was
achieved. The granulation was then dry screened through a 16 mesh
screen and tabletted according to the method set forth in Example
7.
EXAMPLE 11
Intra- and Extragranulation of APAP with MCC-SiO.sub.2 (5% w/w)
[0135] A granulation for compressed tablets was prepared according
to the following formula:
5 INGREDIENTS WEIGHT (GRAMS) MCC-SiO.sub.2 267.9 APAP 114.8
Deionized water 165.8
[0136] One half of the coprocessed MCC-SiO.sub.2 (prepared as in
Example 1A) was added to a Baker-Perkins 10 liter blender and
combined with all of the APAP. The blender impeller was adjusted to
200 rpm and the chopper was set at 1000 rpm. After one minute, the
water was added over 90 seconds using a: rinse bottle. Thereafter,
mixing was continued for an additional 90 seconds. The granulation
was removed from the blender, wet screened through a 12 screen mesh
and then dried in a convection oven for 2-3 hours at 60.degree. C.
until a moisture content of less than 5% was achieved. The
granulation was then dry screened through a 16 mesh screen before
being blended for 10 minutes with the remaining portion of the
coprocessed MCC-SiO.sub.2 in a 2 quart V-blender, removed from the
blender, and tabletted according to the method of Example 7.
EXAMPLE 12
Direct Compression Formulation of APAP with MCC-SiO.sub.2 (5%
w/w)
[0137] A direct compression formulation similar to that set forth
in example 9 was undertaken except that the tablets were prepared
to contain the coprocessed MCC-SiO.sub.2 of Example 1A. The tablet
granulation was prepared according to the following formula:
6 INGREDIENTS WEIGHT (GRAMS) MCC-SiO.sub.2 175.0 APAP 74.5 PRUV
0.5
[0138] As was the case in example 9, five separate tabletting runs
were undertaken using compression forces of 5, 10, 15, 20 and 25 kN
respectively on a Korsch tablet press, (punch size: 3/8" and aim
weight--about 245 mg). Ten tablets from each compression force were
used to carry out the experiment set forth in Example 13.
EXAMPLE 13
Tablet Strength Testing
[0139] Ten tablets from each compression force run for each
formulation prepared in Examples 7-12 were weighed, measured for
diameter and tested for thickness and hardness on the Erweka TBH 30
tablet hardness tester to determine the compressibility of the
microcrystalline cellulose. The results are graphically illustrated
in FIG. 2 as a comparison of tensile strength versus compression
force.
[0140] Referring now to FIG. 2, it can be seen that compressed
tablets made with the inventive coprocessed MCC-SiO.sub.2 have
relatively high tensile strengths when compared to those made with
off-the-shelf MCC. The advantages of the coprocessed MCC-SiO.sub.2
are clearly seen in both direct compression and wet granulation
formulations and especially in wet granulation products.
EXAMPLES 14-16
Diatomaceous Earth
[0141] In these examples, the coprocessing method described in
Example 1A was repeated except that diatomaceous earth of about 40
micron particle size (J.T. Baker, Phillipsburg, N.J. was used as
the source of SiO.sub.2).
7 Diatomaceous Example Earth (wt %) 14 2.0 15 1.0 16 0.5
[0142] The resultant granulates prepared according to Example 1B
were tabletted according to the same method described in Example 6
and evaluated for tensile strength. The products of inventive
Example 3 (MCC-SiO.sub.2 2% w/w) and Example 5 (MCC alone) were
included in FIG. 3 for comparison purposes.
[0143] Referring now to FIG. 3, it can be seen that although the
retention of compressibility afforded by coprocessing diatomaceous
earth is not as great as that provided by colloidal SiO.sub.2
having surface areas of about 200 m.sup.2/g, the coprocessed
MCC-diatomaceous earth nonetheless demonstrates improved
compressibility in wet granulation formulations.
EXAMPLES 17-19
Silica Gel
[0144] In these examples, the coprocessing method described in
Example 1A was repeated using silica gel 200 micron particle size
(VWR Corp., Piscataway, N.J. as the source of SiO).
8 Example Silica Gel (wt %) 17 1 18 2 19 5
[0145] The resultant granulates prepared according to Example 1B
were tabletted according to the same method described in Example 6
and evaluated for tensile strength. The products of inventive
Example 3 (MCC-SiO.sub.2 2% w/w) and Example 5 (MCC alone) were
included in FIG. 4 for comparison purposes.
[0146] Referring now to FIG. 4, it can be seen that the retention
of compressibility afforded by coprocessing with silica gel is well
below that provided by colloidal SiO.sub.2 having surface areas of
about 200 m.sup.2/g. In fact, MCC coprocessed with silica gel
demonstrates compressibility properties about the same as
off-the-shelf MCC in wet granulation formulations.
EXAMPLES 20-22
HS-5 Grade Silicon Dioxide
[0147] In these examples, the coprocessing method described in
example 1 was repeated using HS-5 grade SiO.sub.2 surface area-325
m.sup.2/g (Cabot Corp., Tuscola, Ill.).
9 Example Silica Gel (wt %) 20 2 21 1 22 0.5
[0148] The resultant granulates prepared according to Example 1B
were tabletted according to the same method described in Example 6
and evaluated for tensile strength. The products of inventive
Example 3 (MCC-SiO.sub.2 2% w/w) and Example 5 (off-the-shelf MCC)
were included in FIG. 5 for comparison purposes.
[0149] Referring now to FIG. 5, the retention of compressibility
afforded by coprocessing with HS-5 is comparable to that obtained
using SiO.sub.2 having surface areas of about 200 m.sup.2/g.
EXAMPLES 23-30
Extra-Low Moisture MCC-SiO.sub.2
PROSOLV SMCC.RTM. 90
[0150] PROSOLV SMCC.RTM. 90 (hereinafter "P90") is a commercially
available coprocessed MCC-SiO.sub.2 (2% w/w) product which was
introduced by the Edward Mendell Company in November 1996, and is
currently commercially available from Penwest Pharmaceuticals. P90
is manufactured by preparing an aqueous slurry containing
micrcrystalline cellulose in the form of a wet cake (i.e.,
hydrocellulose or hydrolyzed cellulose) and 2% w/w colloidal
silicon dioxide (based upon the dry weight of the final product).
The slurry is then mixed to allow the materials to become
intimately combined. Then the slurry is spray dried to provide a
particle size, measured by Alpine.TM..sup.2 air jet, of i) not more
than 8% retained on #60 mesh screen (250 .mu.m) and ii) 45.0% to
80.0% retained on #200 mesh screen (75 .mu.m). The median particle
size (by sieve analysis) of this product is in the region of 90
.mu.m. The resulting excipient has no more than a 6% moisture
content (i.e. 6% LOD (loss on drying)).
Example 23
Extra Low Moisture MCC-SiO.sub.2 (LOD 0.9%)
[0151] Approximately 60 grams of the P90 was placed in a high
density polyethylene container with a screw cap (diameter: 60 mm,
height 135 mm (with cap)). The container was placed (without the
cap) in an oven at 80.degree. C. for 48 hours to obtain an extra
low moisture excipient with an LOD (loss on drying) of 0.9% (0.9%
XLMP) in accordance with the present invention.
[0152] The LOD of Example 23 was determined as follows. Two grams
of the 0.9% XLMP was placed in a glass vial with a screw cap
(diameter: 27.5 mm, height: 75 mm (with cap)) and was placed,
without the cap, in an oven at 105.degree. C. for three hours. The
cap was then put on the vial, and the vial (with the cap) was
returned to ambient conditions for 30 minutes prior to determining
the final weight. An LOD (loss on drying) of 0.9% was then measured
by comparing the final weight to the pre-heated weight.
Example 24
Extra Low Moisture MCC-SiO.sub.2 (LOD 1.8%)
[0153] Approximately 60 grams of the P90 was placed in a high
density polyethylene container with a screw cap (diameter: 60 mm,
height 135 mm (with cap)). The container (without the cap) was
placed in an oven at 60.degree. C. for 48 hours to obtain an extra
low moisture excipient with an LOD (loss on drying) of 1.8% (1.8%
XLMP) in accordance with the present invention.
[0154] The LOD of Example 24 was determined as follows. Two grams
of the 1.8% XLMP was placed in a glass vial with a screw cap
(diameter: 27.5 mm, height: 75 mm (with cap)) and was placed,
without the cap, in an oven at 105.degree. C. for three hours. The
cap was then put on the vial, and the vial (with the cap) was
returned to ambient conditions for 30 minutes prior to determining
the final weight. An LOD (loss on drying) of 1.8% was then measured
by comparing the final weight to the pre-heated weight.
Comparative Example 25
[0155] Emcocel.RTM. 90M (hereinafter E90), manufactured by Penwest
Pharmaceuticals, is a conventional, (unaugmented) microcrystalline
cellulose product having a median particle size (by sieve analysis)
in the region of 90 .mu.m.
[0156] Approximately 60 grams of the E90 was placed in a high
density polyethylene container with a screw cap (diameter: 60 mm,
height 135 mm (with cap)). The container was placed (without the
cap) in an oven at 80.degree. C. for 48 hours to obtain an extra
low moisture excipient with an LOD (loss on drying) of 0.9% (0.9%
XLME).
[0157] The LOD of Example 25 was determined as follows. Two grams
of the 0.9% XLME was placed in a glass vial with a screw cap
(diameter: 27.5 mm, height: 75 mm (with cap)) and was placed,
without the cap, in an oven at 105.degree. C. for three hours. The
cap was then put on the vial, and the vial (with the cap) was
returned to ambient conditions for 30 minutes prior to determining
the final weight. An LOD (loss on drying) of 0.9% was then measured
by comparing the final weight to the pre-heated weight.
Example 26
[0158] The excipients of Example 23, 24, 25, as well as
commercially available Emcocel.RTM. XLM 90 and Emcocel 90M
(manufactured by Penwest Pharmaceuticals, LOD=1.3% & 5.7%
respectively, calculated in the same manner as Examples 23-25), and
PROSOLV SMCC.RTM. 90 were compacted as follows. Approximately 6
grams of excipient powder were compacted into tablets with an
Instron 1185 compression machine with 100 kN Load Cell under the
following conditions:
[0159] Load: 100 kN.
[0160] Compression Rate: 10 mm/min.
[0161] Dwell Time: 1 minute.
[0162] Dies: Heat treated silver steel.
[0163] Diameter: 25 mm.
[0164] The tablets compacted from the excipients of Examples 23,
24, 25, Emcocel.RTM. XLM 90, Emcocel.RTM. 90M, and PROSOLV
SMCC.RTM. 90 were then tested with an Instron 1122 with a 500 Kg
Load Cell at 5 mm/min. The weighing, compaction and testing of the
dried powders were achieved within 10 minutes of exposure to
ambient conditions.
Example 27
[0165] A plot of the typical load/deflection data for Examples 23,
25, and commercially available Emcocel 90M, after compaction and
testing in accordance with Example 26, is shown in FIG. 6, with the
underlying data set forth in the following Table:
10 Emcocel 90M Def/mm (Deflection/mm) N (Newtons) 0 0 0.04 171.675
0.14 735.75 0.34 1741.275 0.54 2477.025 0.74 3065.625 0.9
3448.215
Example 25
[0166]
11 Def/mm N 0 0 0.1 480.69 0.2 1030.05 0.4 2089.53 0.6 2918.475
0.71 3325.59
Example 23
[0167]
12 Def/mm N 0 0 0.08 416.925 0.18 1005.525 0.48 2575.125 0.68
3408.975 0.88 4012.29
Example 28
[0168] A plot of the typical load/deflection data for Example 24
(1.8% LOD) and commercially available Emcocel.RTM. 90M (5.7% LOD),
after compaction and testing in accordance with Example 26, is
shown in FIG. 7, with the underlying data set forth in the
following Table:
13 Emcocel 90M Def/mm N 0 0 0.04 188.8425 0.14 863.28 0.24 1429.808
0.34 1888.425 0.44 2293.088 0.54 2643.795 0.64 2940.548 0.74 3237.3
0.84 3480.098 0.91 3614.985
Example 24
[0169]
14 0 0 0.09 593.505 0.19 1240.965 0.29 1861.448 0.39 2400.998 0.49
2913.57 0.59 3372.188 0.69 3776.85 0.79 4181.513 0.89 4505.243 0.94
4640.13
[0170] The LOD of Example 24 and Emcocel 90M were calculated as
follows:
15 Weights/g E90M Example 24 Container and lid 20.0144 20.3019 And
Powder 22.054 22.3533 Weight Powder 2.0396 2.0514 After Heating
21.9385 22.3171 Weight Loss 0.1157 0.0362 LOD 5.70% 1.80%
[0171] It should be noted that the same procedure has been used to
calculate the LOD in each of Examples 23-31, and FIGS. 6-11.
Example 29
[0172] A plot of the relative density specific stress/strain data
for Examples 23, 25, and commercially available Emcocel 90M, after
compaction and testing in accordance with Example 26, is shown in
FIG. 8, with the underlying data set forth in the following
Table:
16 Emococel 90M Relative Density Specifc Def/mm Strain/% Squares N
Stress/MPa Stress/MPa Density = 1.44 gcm.sup.-3 thickness (t) =
8.51 mm Relative Density RD = 0.917 0 0 0 0 0 0 0.04 0.159363 3.5
171.675 0.803718 0.876465 0.14 0.557769 15 735.75 3.444506 3.756277
0.34 1.354582 35.5 1741.275 8.151998 8.889856 0.54 2.151394 50.5
2477.025 11.5965 12.64613 0.74 2.948207 62.5 3065.625 14.35211
15.65116 0.9 3.585657 70.3 3448.215 16.14325 17.60442 Example 25
Density = 1.33 gcm.sup.-3 t = 9.15 mm RD = 0.847 0 0 0 0 0 0 0.1
0.398406 9.8 480.69 2.093005 2.47108 0.2 0.796813 21 1030.05
4.485011 5.295172 0.4 1.593625 42.6 2089.53 9.098165 10.74163 0.6
2.390438 59.5 2918.475 12.70753 15.00299 0.71 2.828685 67.8 3325.59
14.48018 17.09584 Example 23 Density = 1.33 gcm.sup.-3 t = 9.12 mm
RD = 0.847 0 0 0 0 0 0 0.08 0.318725 8.5 416.925 1.821333 2.150334
0.18 0.717131 20.5 1005.525 4.392627 5.1861 0.48 1.912351 52.5
2575.125 11.24941 13.28148 0.68 2.709163 69.5 3408.975 14.89208
17.58214 0.88 3.505976 81.8 4012.29 17.52765 20.6938
[0173] FIG. 9 shows a comparison of tensile strength data for
Example 23, Example 25, PROSOLV SMCC.RTM. 90, Emcocel.RTM. 90M, and
Emcocel.RTM. XLM90. As illustrated therein, the extra low moisture
MCC-SiO.sub.2 in accordance with the present invention (Example
23), exhibited a higher failure load, higher tensile strength a,
and higher energy of failure than Emcocel.RTM. 90M, Example 25
(Emcocel 90M dried to 0.9% LOD) and Emcocel.RTM. XLM90 while
providing a moisture content of only 0.9% (LOD). In addition,
Example 23 exhibits a deflection which is comparable to
Emcocel.RTM. 90M (which is known to have a moisture content of 6%
or less), and which is superior to both Example 25 (Emcocel.RTM. 90
dried to 0.9 LOD) and Emcocel.RTM. XLM 90. Therefore, Example 23
(0.9% LOD) and Example 24 (1.8% LOD) show improved compactibility
when compared to Emcocel.RTM. 90M and Emcocel.RTM. XLM90.
[0174] FIGS. 10 and 11 show, respectively, the density specific
stress and the relative density specific stress of Example 23,
Example 0.25, PROSOLV SMCC.RTM. 90, Emcocel.RTM. 90M, Emcocel.RTM.
XLM90, and Emcocel.RTM. HD90 (a high density microcrystalline
cellulose available from Penwest Pharmaceuticals).
[0175] While there have been described what are presently believed
to be the preferred embodiments of the invention, those skilled in
the art will realize that changes and modifications may be made
thereto without departing from the spirit of the invention. It is
intended to claim all such changes and modifications that fall
within the true scope of the invention.
* * * * *